The problem is deceptively simple: Europe's healthcare system is a maze. Different countries, different regulations, fragmented public records scattered across thousands of registries. For pharmaceutical companies trying to understand where doctors practice, which hospitals specialize in what, or how to efficiently reach vaccination sites, it's a data wilderness.
Lasken.AI, a Zagreb-based startup, thinks it has found a path through. On July 22, the company announced it had closed a seed funding round co-led by GapMinder Ventures and Fil Rouge Capital. Neither the startup nor its investors disclosed the amount—a common practice for earlier-stage European rounds where founders prefer to keep valuations quiet.
What Lasken.AI is building amounts to what co-founder Patric Jarchow calls a "digital librarian" for healthcare data: structured, continuously refreshed datasets pulled from publicly available information on Europe's sprawling network of medical institutions. Right now, the platform tracks more than 400,000 healthcare organizations and roughly 2 million professionals in Germany alone, processing upward of 500 billion words from public sources. By year's end, the company aims to extend that coverage to around 2.5 million organizations spanning Europe's five largest pharmaceutical markets.
It's an ambitious target, perhaps more ambitious than most seed-stage startups would comfortably admit. But Jarchow isn't new to this world. Before launching Lasken.AI in 2025, he spent years leading innovation at IQVIA Germany and previously held global multi-channel strategy roles at Merck KGaA—positions that gave him a front-row seat to just how messy healthcare data can be. His co-founder, Leonard Unger, brings product and startup-building experience to the mix. Together, they've assembled a small team operating out of both Zagreb and Munich, currently numbering somewhere between two and ten employees depending on how you count contractors and advisors.
Turning Fragments Into Decisions
The company's pitch centers on transformation: taking fragmented public healthcare records and reshaping them into what it describes as "decision-ready datasets." Clients—pharmaceutical companies, healthtech firms, contract sales organizations, consultancies—use the platform to answer questions that would otherwise require weeks of manual research. Which pharmacies have the highest vaccination potential? Where are oncology physicians clustered by therapy focus, practice size, or digital engagement? How have those patterns shifted over the past six months?
Lasken.AI doesn't generate this intelligence through surveys or proprietary partnerships. Instead, it scrapes, structures, and continuously updates information that's technically public but practically inaccessible at scale. The platform tracks changes over time, layering in socioeconomic context and organizational characteristics to build what amount to dynamic profiles of Europe's healthcare ecosystem.
It's the kind of infrastructure play that doesn't make headlines the way consumer apps do. But for pharma and healthtech companies navigating Europe's regulatory patchwork, it solves a tangible pain point. Germany alone spends more than 10% of its GDP on healthcare—north of €400 billion annually—and operates an estimated 1,900 hospitals staffed by roughly 430,000 doctors. Mapping that comprehensively, in real time, remains notoriously difficult.
What Comes Next
The fresh seed capital will go toward product development and a commercial push in Germany, with expansion into other major European markets planned shortly after. Lasken.AI is building new capabilities around semantic understanding, organizational intelligence, persona modeling, and what it terms "advanced commercial analytics." The company recently brought on Vladimir Novakovic as Chief Data & Analytics Officer, a hire that signals a focus on technical depth as much as market expansion.
Fil Rouge Capital, an early-stage investor based in Zagreb managing over €100 million, previously backed Lasken.AI at the pre-seed stage and doubled down in this round. GapMinder Ventures, which focuses on Central and Eastern Europe, launched its €80 million Fund II in 2024 with support from the European Investment Fund and InvestEU. For both firms, the bet reflects a broader thesis: data infrastructure for Europe's healthcare sector is underbuilt, and the regulatory fragmentation that makes the market hard to navigate also creates moats for companies that figure it out.
The deal comes at a moment when investors are paying closer attention to B2B healthcare data plays—less sexy than AI-powered diagnostics, maybe, but potentially more defensible. Lasken.AI was selected from among 150 startups at PODIM 2026 and attended the Health.Tech Global Summit in Lisbon earlier this year, signals that the company is gaining traction in the European startup ecosystem even as it remains relatively unknown outside it.
Whether Lasken.AI can deliver on its year-end expansion goals—and whether the market will pay enough for structured healthcare data to justify venture-scale returns—remains an open question. But for a team of fewer than a dozen people, the ambition is already clear: build the definitive map of Europe's healthcare landscape, one public record at a time.
